Sharma, Surendra K.
Katoch, Kiran
Sarin, Rohit
Balambal, Raman
Kumar Jain, Nirmal
Patel, Naresh
Murthy, Kolluri J. R.
Singla, Neeta
Saha, P. K.
Khanna, Ashwani
Singh, Urvashi
Kumar, Sanjiv
Sengupta, A.
Banavaliker, J. N.
Chauhan, D. S.
Sachan, Shailendra
Wasim, Mohammad
Tripathi, Sanjay
Dutt, Nilesh
Jain, Nitin
Joshi, Nalin
Penmesta, Sita Ram Raju
Gaddam, Sumanlatha
Gupta, Sanjay
Khamar, Bakulesh
Dey, Bindu
Mitra, Dipendra K.
Arora, Sunil K.
Bhaskar, Sangeeta
Rani, Rajni
Article History
Received: 17 January 2017
Accepted: 28 April 2017
First Online: 13 June 2017
Competing Interests
: Funding agency was involved in designing of study protocol, management of the conduct of the study including progress, DSMB meetings, supervising and funding of monitoring activities, collection of study protocols and final analysis of the data. Dr. Bindu Dey was an Adviser in Department of Biotechnology, the funding agency. Bakulesh Khamar is the Executive Director, Research, at Cadila Pharmaceuticals Ltd., Ahmadabad, India, company which has been licensed to manufacture <i>MIP</i>. However, he was not involved in clinical study directly. Sanjay Gupta of Catalyst Clinical Services Pvt. Ltd., New Delhi, India was involved in collection of data from various clinical sites, collating and analysis of the data. However, there were no potential competing financial interests as such for the other authors involved in carrying out the project.